Mechelen, Belgium; 21 April 2017, 22.01 CET; regulated information - Galapagos NV (Euronext: GLPG; Nasdaq: GLPG) announced today the closing of its underwritten public offering of 4,312,500 American Depositary Shares (“ADSs”), at a price of $90.00 per ADS, before underwriting discounts, for gross proceeds of €363.9 million. This includes the full exercise of the underwriters’ option to purchase additional ADSs. All of the ADSs were offered by Galapagos.
Each of the ADSs offered represents the right to receive one ordinary share.
Galapagos’ ADSs are currently listed on the NASDAQ Global Select Market under the symbol “GLPG” and Galapagos’ ordinary shares are currently listed on Euronext Amsterdam and Euronext Brussels.
Morgan Stanley acted as sole book-running manager for the public offering.
The securities were offered pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on 17 April 2017. The final prospectus supplement relating to the offering was filed with the SEC on 18 April 2017 and is available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, United States, Attention: Prospectus Department.
This press release does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 510 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.
CONTACT
Investors:
Elizabeth Goodwin
VP IR & Corporate
Communications
+1 781 460 1784
Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
